Dermapharm Holding SE (DMP.DE)

EUR 39.2

(1.82%)

Gross Profit Summary of Dermapharm Holding SE

Dermapharm Holding SE's latest annual gross profit in 2023 was 342.86 Million EUR , down -48.12% from previous year.
Dermapharm Holding SE's latest quarterly gross profit in 2024 Q2 was 80.61 Million EUR , down -26.83% from previous quarter.
Dermapharm Holding SE reported a annual gross profit of 660.83 Million EUR in annual gross profit 2022, up 6.47% from previous year.
Dermapharm Holding SE reported a annual gross profit of 620.69 Million EUR in annual gross profit 2021, up 33.92% from previous year.
Dermapharm Holding SE reported a quarterly gross profit of 110.17 Million EUR for 2024 Q1, up 50.76% from previous quarter.
Dermapharm Holding SE reported a quarterly gross profit of 175.02 Million EUR for 2023 Q3, up 11.97% from previous quarter.

Annual Gross Profit Chart of Dermapharm Holding SE (2023 - 2014)

Historical Annual Gross Profit of Dermapharm Holding SE (2023 - 2014)

Year	Gross Profit	Gross Profit Growth
2023	342.86 Million EUR	-48.12%
2022	660.83 Million EUR	6.47%
2021	620.69 Million EUR	33.92%
2020	463.48 Million EUR	20.79%
2019	383.72 Million EUR	28.01%
2018	299.76 Million EUR	35.35%
2017	221.47 Million EUR	10.17%
2016	201.03 Million EUR	11.81%
2015	179.8 Million EUR	5.13%
2014	171.02 Million EUR	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	80.61 Million EUR	-26.83%
2024 Q1	110.17 Million EUR	50.76%
2023 Q3	175.02 Million EUR	11.97%
2023 Q4	73.08 Million EUR	-58.25%
2023 FY	342.86 Million EUR	-48.12%
2023 Q1	212.38 Million EUR	6.82%
2023 Q2	156.31 Million EUR	-26.4%
2022 Q1	146.62 Million EUR	-21.4%
2022 FY	660.83 Million EUR	6.47%
2022 Q2	152.12 Million EUR	3.75%
2022 Q4	198.82 Million EUR	21.78%
2022 Q3	163.26 Million EUR	7.33%
2021 Q4	186.54 Million EUR	18.82%
2021 FY	620.69 Million EUR	33.92%
2021 Q2	143.74 Million EUR	7.75%
2021 Q3	157 Million EUR	9.22%
2021 Q1	133.41 Million EUR	0.22%
2020 Q4	133.11 Million EUR	14.91%
2020 FY	463.48 Million EUR	20.79%
2020 Q3	115.84 Million EUR	7.01%
2020 Q2	108.25 Million EUR	1.87%
2020 Q1	106.27 Million EUR	2.53%
2019 Q2	91.41 Million EUR	0.26%
2019 FY	383.72 Million EUR	28.01%
2019 Q1	91.17 Million EUR	14.29%
2019 Q4	103.64 Million EUR	6.31%
2019 Q3	97.49 Million EUR	6.65%
2018 Q4	79.77 Million EUR	6.04%
2018 FY	299.76 Million EUR	35.35%
2018 Q2	71.26 Million EUR	-3.03%
2018 Q1	73.49 Million EUR	23.87%
2018 Q3	75.23 Million EUR	5.56%
2017 Q2	53.83 Million EUR	-4.46%
2017 Q3	51.95 Million EUR	-3.5%
2017 Q1	56.35 Million EUR	4.69%
2017 FY	221.47 Million EUR	10.17%
2017 Q4	59.33 Million EUR	14.21%
2016 FY	201.03 Million EUR	11.81%
2016 Q4	53.82 Million EUR	0.0%
2015 FY	179.8 Million EUR	5.13%
2014 FY	171.02 Million EUR	0.0%

Peer Gross Profit Comparison of Dermapharm Holding SE

Name	Gross Profit	Gross Profit Difference
MPH Health Care AG	180.33 Million EUR	-90.129%
Apontis Pharma AG	-3.33 Million EUR	10376.976%
Evotec SE	175.05 Million EUR	-95.863%
MERCK Kommanditgesellschaft auf Aktien	11.66 Billion EUR	97.062%
PharmaSGP Holding SE	91.63 Million EUR	-274.151%
SynBiotic SE	1.5 Million EUR	-22660.017%